Understand the source comparison
Best Research Peptides for Andropause Research: Comparison
CJC-1295 GHRH analog. Extends GH pulse duration Lean mass preservation, sleep quality improvement 1–2mg subcutaneous weekly 52-week trial: 92% lean mass retention vs 78% control Gold standard for GH axis restoration without receptor desensitization Ipamorelin
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- CJC-1295
- GHRH analog. Extends GH pulse duration
- Lean mass preservation, sleep quality improvement
- 1–2mg subcutaneous weekly
- 52-week trial: 92% lean mass retention vs 78% control
- Gold standard for GH axis restoration without receptor desensitization
- Ipamorelin
- Ghrelin mimetic. Stimulates GH release without cortisol/prolactin elevation
- Anti-sarcopenia, metabolic support
- 300mcg subcutaneous daily
- JCEM study: 25–40% improvement in deep sleep architecture
- Cleanest side effect profile among secretagogues
- MK-677
- Oral ghrelin receptor agonist
- Same as ipamorelin but oral administration
- 10–25mg oral daily
- Phase 2 data: sustained IGF-1 elevation for 18+ months
- Convenient dosing but appetite stimulation limits tolerability for some
- BPC-157
- Angiogenic peptide. Promotes fibroblast proliferation
- Connective tissue repair, chronic tendinopathy
- 250–500mcg subcutaneous twice daily
- Animal models: 30–40% faster tendon healing
- Best evidence in soft tissue injury; limited human RCTs
- TB-500
- Thymosin Beta-4 fragment. Upregulates actin polymerization
- Post-injury recovery, joint pain reduction
- 2–5mg subcutaneous twice weekly for 4 weeks
- Case reports show pain reduction in chronic MSK conditions
- Mechanism well-understood; clinical evidence mostly observational
- MOTS-c
- Mitochondrial peptide. Activates AMPK pathway
- Metabolic flexibility, insulin sensitivity
- 10mg subcutaneous 3× weekly
- USC trial: 12% VO2 max improvement, 8% glucose reduction
- Emerging evidence; strongest for metabolic dysfunction
- Humanin
- Mitochondrial peptide. Reduces oxidative stress
- Cardiovascular protection, neuroprotection
- 2–4mg subcutaneous daily
- Early trials show reduced inflammatory markers (IL-6, TNF-alpha)
- Promising but still early-phase research